MALVERN, Pa., March 06, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today that the U.S. Food and Drug Administration (FDA) has recently granted Breakthrough Device Designation for the Company’s NeuroStar Advanced Therapy System for the treatment of bipolar depression.
The FDA’s Breakthrough Device Program is intended to help patients and healthcare providers receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The program creates an expedited pathway for prioritized FDA review of the NeuroStar Advanced Therapy clinical trial program. Neuronetics has submitted initial clinical plans for discussion with the FDA.
“We are delighted that the FDA has accepted our application for Breakthrough Device Designation and look forward to working closely with them to provide a potential solution for people with bipolar depression. This potential new treatment indication for NeuroStar means that millions of people with bipolar disorder who do not respond to medications may have a proven, non-drug treatment available to them,” said Yelena Tropsha, Vice President, Commercial Access. “The Breakthrough Device Designation is an important milestone that further supports our mission of renewing lives by transforming neurohealth.”
Read the full article at this link
March 5, 2002
Highlighting: Anne Venner Ph.D.